BridgeMD
New treatment option for Subarachnoid Hemorrhage, Aneurysmal
Official title Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
ClinicalTrials.gov ID: NCT06359782
What this study is testing
What is C1 Esterase Inhibitor Injection [Cinryze]?
C1 Esterase Inhibitor Injection [Cinryze] is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for subarachnoid hemorrhage, aneurysmal.
Also referred to as Cinryze.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes for patients, like cognitive decline. This is caused by early brain injury (EBI) followed by delayed cerebral ischemia (DCI).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan;
- Age ≥ 18 years on admission;
- WFNS grade 1-5.
You likely can't join if
- Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological...
- Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings...
- Participation in another clinical therapeutic study;
- Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission
- Patients with a known hereditary complement deficiency (including hereditary angioedema);
- Patients with a history of sensibility to blood products or C1-inhibitor;
See the full eligibility criteria
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan;
- Age ≥ 18 years on admission;
- WFNS grade 1-5.
- Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (not originated from an aneurysm...
- Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (does not occur spontaneous)
- Participation in another clinical therapeutic study;
- Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission
- Patients with a known hereditary complement deficiency (including hereditary angioedema);
- Patients with a history of sensibility to blood products or C1-inhibitor;
- Patients with a history of thrombosis (when known at time of inclusion);
- Pregnant woman
The study team makes the final eligibility decision.
Where it's taking place
- The Hague, South Holland, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include The Hague, South Holland, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.